CN1840162A - Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use - Google Patents
Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use Download PDFInfo
- Publication number
- CN1840162A CN1840162A CNA2006100112498A CN200610011249A CN1840162A CN 1840162 A CN1840162 A CN 1840162A CN A2006100112498 A CNA2006100112498 A CN A2006100112498A CN 200610011249 A CN200610011249 A CN 200610011249A CN 1840162 A CN1840162 A CN 1840162A
- Authority
- CN
- China
- Prior art keywords
- ginger
- compound
- cape jasmine
- fermented soybean
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title abstract description 37
- 150000001875 compounds Chemical class 0.000 title abstract description 14
- 244000068988 Glycine max Species 0.000 title description 35
- 235000010469 Glycine max Nutrition 0.000 title description 35
- 244000111489 Gardenia augusta Species 0.000 title description 31
- 235000018958 Gardenia augusta Nutrition 0.000 title description 31
- 235000006886 Zingiber officinale Nutrition 0.000 title description 29
- 235000008397 ginger Nutrition 0.000 title description 29
- 238000002360 preparation method Methods 0.000 title description 16
- 244000273928 Zingiber officinale Species 0.000 title 1
- 229930182489 iridoid glycoside Natural products 0.000 abstract description 8
- 229930182490 saponin Natural products 0.000 abstract description 8
- 150000007949 saponins Chemical class 0.000 abstract description 8
- 150000003505 terpenes Chemical class 0.000 abstract description 7
- 239000000341 volatile oil Substances 0.000 abstract description 6
- 150000008145 iridoid glycosides Chemical class 0.000 abstract description 5
- 230000029087 digestion Effects 0.000 abstract description 3
- 229930003944 flavone Natural products 0.000 abstract description 3
- 150000002213 flavones Chemical class 0.000 abstract description 3
- 235000011949 flavones Nutrition 0.000 abstract description 3
- 208000002296 eclampsia Diseases 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 abstract 1
- 235000007586 terpenes Nutrition 0.000 abstract 1
- 241000234314 Zingiber Species 0.000 description 28
- 239000003814 drug Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- 210000000582 semen Anatomy 0.000 description 13
- 238000000605 extraction Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000010828 elution Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 8
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 8
- 235000002780 gingerol Nutrition 0.000 description 8
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 8
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 8
- 235000008696 isoflavones Nutrition 0.000 description 8
- 239000012567 medical material Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 239000003463 adsorbent Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 229930187719 Soyasaponin Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 2
- 229930001895 zingiberene Natural products 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical group COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010049704 Gallbladder polyp Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- JZZIHCLFHIXETF-UHFFFAOYSA-N dimethylsilicon Chemical compound C[Si]C JZZIHCLFHIXETF-UHFFFAOYSA-N 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical group C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000013976 polyp of gallbladder Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000004622 zingiberene derivatives Chemical class 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a compound extract for tranquillization, infantile eclampsia resistance and digestion promotion, which comprises 5-95% of iridoid glycosides, 1-90% of saponins, 1-90% of terpenes, 1-90% of flavones and 1-90% of volatile oil.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly, the present invention relates to compound total extract of compound cape jasmine, ginger and fermented soybean and its preparation thereof.
Background technology
Cape jasmine, ginger and fermented soybean soup is made up of Fructus Gardeniae, Semen Sojae Preparatum, Rhizoma Zingiberis Recens, be one of basic side of treatise on Febrile Diseases syndrome of decoction ZHI ZI (Fructus gardeniae) CHI (Semen sojae preparatum) class, increased Rhizoma Zingiberis Recens simply with respect to the main formula Decoction of Capejasmine and Fermented Soybean, prescription Fructus Gardeniae hardship with pathogenic fire purging, coldly loose with heat clearing away and hot sweet a surname of fragrant fermented soya beans, salted or other wise, expelling pathogenic factors from the exterior and increased the cold expelling that induces sweat, the warming middle-JIAO to arrest vomiting of Rhizoma Zingiberis Recens, the effect of preventing phlegm from forming and stopping coughing on the function basis that goes out, make its function cure mainly from the expelling pathogenic factors from the exterior of the Decoction of Capejasmine and Fermented Soybean expel the heat-evil, removing stagnation to relieve restlessness, transfer clearing away the stagnated heat, stomach function regulating preventing or arresting vomiting to, effects such as calm, analgesic, antiinflammatory, blood pressure lowering, infection, antifungal have been arranged.Modern study shows in this prescription that its main pharmacodynamics composition has become through people's extensive studies and confirms to have multiple bioactive material, show 1. effect to liver as iridoid glycosides pharmacological research in the Fructus Gardeniae: the function of gallbladder promoting hepatoprotective increases enzyme activity and bile secretion, increase Y albumen, the Z protein content, promote pancreatic secretion 2. to the gastrointestinal effect: the gastric acid inhibitory secretion, the two-ways regulation gastrointestinal motility is 3. to cardiovascular effect: reduce myocardial contraction, bring high blood pressure down, prevent that atherosclerosis is 4. to central nervous system's effect: tranquilizing soporific, antipyretic-antalgic be antiinflammatory action and to the effect of pathogenic microorganism 5..Be usually used in diseases such as hepatitis, coronary heart disease, gastropathy are hemorrhage, psychosis, antiinflammatory antiviral in clinical; One-tenth such as the Saponin in the Semen Sojae Preparatum, isoflavone, polypeptide are grouped into, pharmacological research shows 1. functions of lowering blood-fat and reducing weight, and 2. the prevention of hyperlipemia is reduced 3. 4. 5. mutation and antitumaous effect of immunoregulation effect of antioxidation and antivirus action of anticoagulation, antithrombotic and antidiabetic effect; Zingiberone in the Rhizoma Zingiberis Recens; gingerol; zingiberene; compositions such as gingerol; 1. pharmacological research shows the effect to liver: the hepatocyte of function of gallbladder promoting hepatoprotective reparation damage is 2. to the gastrointestinal effect: anti-alimentary tract ulcer; promote gastrointestinal motility; the protection mucomembranous cell; preventing or arresting vomiting is told 3. to cardiovascular effect: the heart tonifying blood pressure lowering; suppress vasoconstriction; blood fat reducing; prevent that atherosclerosis is 4. to immune effect: can improve body nonspecific immunity function; specific immune function there is dual regulation; the activity level that can improve natural killer cell 5. antiinflammatory action 6. to central nervous system's effect: have calmness; analgesic; analgesia and the 7. effect of resisting pathogenic microbes of anticonvulsant action: antibacterial; the protozoacide effect is 8. to the respiratory system effect: analgesic; unimpeded respiratory tract, relieving cough and resolving phlegm, excited respiratory center is antitumor action etc. 9..Be usually used in diseases such as digestive system disease, cardiovascular disease, psychosis, antiinflammatory antiviral, antitumor such as gastrointestinal in clinical.But yet there are no the Chinese patent medicine of cape jasmine, ginger and fermented soybean now on the market.
Summary of the invention
The present invention is directed to the blank in the said goods field, a kind of cape jasmine, ginger and fermented soybean total extract and preparation thereof are provided, the patient can be cured timely, remove the fatigue that boils decoction from, its curative effect is higher than the decoction that Chinese medicine prescription commonsense method boils simultaneously.
The present invention also provides the preparation method of this total extract.
Compound total extract of compound cape jasmine, ginger and fermented soybean, it mainly contains the 5%-95% iridoid glycosides, 1%-90% Saponin, 1%-90% terpenoid, 1%-90% flavonoid and 1%-90% volatile oil.
Described iridoid glycoside apoplexy due to endogenous wind contains the 10%-95% gardenoside, mainly is soyasaponins in the Saponin, mainly is (4-hydroxy-3-methoxyphenyl)ethyl methyl ketone in the terpenoid, mainly is soybean isoflavone in the flavonoid, mainly is gingerol and zingiberene in the volatile oil.
Wherein gardenoside content is 10%-20%, and soybean isoflavone is 2%-10%, and gingerol is 1%-8%.
The preparation method of compound total extract of compound cape jasmine, ginger and fermented soybean is characterized in that concentrating after Fructus Gardeniae, Semen Sojae Preparatum and Rhizoma Zingiberis Recens are with solvent extraction centrifugal, and after macroporous resin bed solvent elution, concentrate drying gets final product.
The preparation method of compound total extract of compound cape jasmine, ginger and fermented soybean is characterized in that Fructus Gardeniae, Semen Sojae Preparatum and Rhizoma Zingiberis Recens place supercritical CO
2In the abstraction instrument, adopt resin adsorption method, add solvent extraction.
Described resin is a D-101 type adsorbent resin, XAD-2 type adsorbent resin, CHP-20P type adsorbent resin, SP825 type adsorbent resin or HP-20 type adsorbent resin.
The weight fraction ratio of described Fructus Gardeniae, Semen Sojae Preparatum and Rhizoma Zingiberis Recens is 1 part-5 parts: 1 part-3 parts: 1 part-5 parts.
Described solvent is the one or more combination in water, methanol, ethanol, n-butyl alcohol, the acetone.
Above-mentioned compound recipe cape jasmine, ginger and fermented soybean extract can be assisted with pharmaceutically acceptable carrier and is made into preparation.
The dosage form of described preparation is tablet, drop pill or capsule.
Described extract is preparation spiritual neural class disease of treatment such as neurasthenia, anxiety neurosis, depression etc., respiratory system disease such as influenza, upper respiratory tract infection etc., digestive system disease such as acute or chronic gastritis, bacillary dysentery, gastric ulcer, dyspepsia, vomiting, gallbladder inflammation and polyp, jaundice etc., person in middle and old age's common disease such as hypomnesis, senile dementia, climacteric syndrome, osteoporosis, insomnia, hepatitis, coronary heart disease, hyperlipidemia, hypertension, heart failure, tumor, dermatitis, alopecia, acne, chloasma, mucocutaneous antibacterial, the application in the medicine of burning of fungal infection or wound.
The inventor is on the basis of inheriting tradition Chinese medicine elite, the utilization modern science and technology are extracted the effective ingredient in this prescription, as the iridoid glycosides in the Fructus Gardeniae, Saponin in the Semen Sojae Preparatum, soybean isoflavone, polypeptide etc., component such as volatile oil, terpenoid becomes the modern Chinese medicine product with its exploitation in the Rhizoma Zingiberis Recens.
The total extract that the inventive method obtains is a raw material with Fructus Gardeniae, Semen Sojae Preparatum, Rhizoma Zingiberis Recens, with iridoid glycoside constituents, Saponin constituents, ter penoids, flavonoid and volatile oil component is main active, wherein the iridoid glycosides component content can reach 5-95%, and wherein gardenoside content is 10-95% in the iridoid glycoside constituents; The Saponin constituents can reach 1-90%, and wherein the Saponin constituents comprises soyasaponins etc.; Ter penoids can reach 1-90%, and wherein ter penoids comprises (4-hydroxy-3-methoxyphenyl)ethyl methyl ketone etc.; Flavones ingredient can reach 1-90%, and wherein flavones ingredient comprises soybean isoflavone etc.; The volatile oil composition can reach 1-90%, comprising compositions such as gingerol, zingiberenes.
The invention provides two kinds of methods that obtain extract of the present invention.Method one: Fructus Gardeniae, Semen Sojae Preparatum and Rhizoma Zingiberis Recens concentrate after with solvent extraction centrifugal, and after macroporous resin bed solvent elution, concentrate drying gets final product.By the absorption and the solvent elution of macroporous resin bed, the composition that major part is not had drug effect is adsorbed on the resin, and simultaneously above-mentioned active component is got off by solvent elution, makes that active ingredient has obtained purification in the extract.Method two: Fructus Gardeniae, Semen Sojae Preparatum and Rhizoma Zingiberis Recens are placed supercritical CO
2In the abstraction instrument, add solvent extraction.Resin separation purification technology and supercritical extraction technique in the extraction process of the present invention; all are one of crucial isolation technics of the modernization of Chinese medicine; its technology and equipment are advanced practical; enrichment the prescription in effective component group; can improve drug action; medical material utilization rate and reducing production costs; Chinese medicine is made the modernized dosage form that meets international standard; help also simultaneously that each medicine carries out clear and definite quantitative analysis among the other side; the standard that improves the quality is equipped with; can make the tradition prescription carry out further clinical application research such as the release of oral administration intestinal specificity controlled release drug; specific part begins degraded in vivo; discharge; guaranteed absorption strength; the medicine of protecting some easily to degrade under one's belt and losing efficacy, dual absorption hydrolyzate etc., dose will be reduced to about 1 gram every day in addition; broken through the big and thick tradition image of Chinese medicine; be easy to the patient and accept, meet the rhythm of the modern life, reduce patient's gastrointestinal drug and absorb the metabolism burden.Can see that thus the present invention has selected Chinese medicine advantage field, the modernized standard that possesses old prescription, new technology, new adjuvant, new equipment, effective ingredient is clear, effect is clear and definite, no obvious toxic-side effects, meet Chinese medicine modernization development in science and technology thinking and modernization of Chinese medicine industrial development direction, have very strong clinical value and exploitation future.
Extract of the present invention is to the animal central nervous system digestive system of unifying, and antiphlogistic influence test is found, this is subjected to multiple pharmacologically active effects such as the reagent thing has tangible calmness, calms the nerves, convulsion, antiinflammatory, facilitating digestion function, and there is not obvious toxic-side effects, animal normal physiological index there is not obvious influence, about its animal experiment effective dose 100mg/kg, be equivalent to about the clinical 10-20mg/kg of people.
The specific embodiment
Further specify the present invention below by embodiment.It should be understood that embodiments of the invention are to be used to illustrate the present invention rather than limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Except as otherwise noted, the percent among the present invention is percetage by weight.
The preparation of embodiment 1 cape jasmine, ginger and fermented soybean total extract (1)
Fructus Gardeniae, Semen Sojae Preparatum, Rhizoma Zingiberis Recens medical material or decoction pieces or process of preparing Chinese medicine decoction pieces are pulverized (three's ratio is 1.5: 1: 1.5), cross 20 mesh sieves, put and add ethanol extraction in the extraction pot, concentrate extracting solution centrifugal, ethanol elution reclaims after crossing the macropore resin bed, the dry extract that gets.
Extraction conditions: concentration of alcohol 15-80%, ethanol consumption 3-15 be doubly to the medical material amount, and extraction time 1-3 hour, extraction time 1-4 time.
The condition of concentrating: be concentrated into relative density 0.9-1.3
Centrifugal condition: centrifugal rotational speed 3000-30000rpm, centrifugation time 15-45min
Elution requirement: eluent concentration of alcohol 10-90%, eluent consumption 3-15 are doubly to medical material amount recovering condition: reclaim relative density 1.0-1.4
Experimental result: sample yield 5%, gardenoside content 20%, isoflavone content 6%, gingerol content 1%.
The preparation of embodiment 2 cape jasmine, ginger and fermented soybean total extracts (1)
With Fructus Gardeniae, Semen Sojae Preparatum, Rhizoma Zingiberis Recens medical material or decoction pieces or concoct decoction pieces and pulverize (three's ratio is 4: 1: 2), cross 20 mesh sieves, put and add ethanol extraction in the extraction pot, extracting solution is concentrated centrifugal, cross the macropore resin bed after ethanol elution reclaim dry extract.
Extraction conditions: concentration of alcohol 15-80%, ethanol consumption 3-15 be doubly to the medical material amount, and extraction time 1-3 hour, extraction time 1-4 time.
The condition of concentrating: be concentrated into relative density 0.9-1.3
Centrifugal condition: centrifugal rotational speed 3000-30000rpm, centrifugation time 15-45min
Elution requirement: eluent concentration of alcohol 10-90%, eluent consumption 3-15 are doubly to medical material amount recovering condition: reclaim relative density 1.0-1.4
Experimental result: sample yield 5%, gardenoside content 60%, isoflavone content 3%, gingerol content 2%.
The preparation of embodiment 3 cape jasmine, ginger and fermented soybean total extracts (2)
Fructus Gardeniae, Semen Sojae Preparatum, Rhizoma Zingiberis Recens medical material or decoction pieces or process of preparing Chinese medicine decoction pieces are pulverized (ratio of the two is 1: 2: 1), cross 20 mesh sieves, put supercritical CO
2Add alcohol extraction in the abstraction instrument;
Extraction conditions: pressure: 35Mpa, temperature: 45 ℃ (± 3 ℃);
Separation condition: the first separating still separation condition: pressure: 10Mpa, temperature: about 45 ℃;
The second separating still condition: pressure: 5Mpa, temperature: 40 ℃ (± 3 ℃);
Collect the second extraction kettle extract, sucking filtration, centrifugal, get oil reservoir and promptly get total extract (3).
Experimental result: sample yield 3%, gardenoside content 14%, isoflavone content 6%, gingerol content 5%.
The preparation of embodiment 4 cape jasmine, ginger and fermented soybean total extract tablets
Get the cape jasmine, ginger and fermented soybean total extract, mix with adjuvants such as lactose, magnesium stearate, microcrystalline Cellulose and add tablet forming, put into coating pan and add the coating solution coating.Nearly pathogenic wind-warm degree: 40 ℃, atomizing pressure: 3.5Kg, sheet bed tempertaure: 35 ℃, rotating speed: 4-10 minute, tablet weightening finish: 8%.The result shows: the smooth exquisiteness of tablet appearance, hide fully, and disintegrate is up to specification.
The preparation of embodiment 5 cape jasmine, ginger and fermented soybean total extract drop pill
Get cape jasmine, ginger and fermented soybean grass extract, with adjuvant heating and melting such as Polyethylene Glycol, mixed proportion stirs, in the impouring drop pill machine, splash under 80 ℃ of constant temperature in 5 ℃ of dimethyl-silicon wet goods condensed fluid, drip 35 droplets/minute of speed, drip apart from 5cm, leach drop pill, clean condensed fluid, packing is made drop pill promptly.
The result shows: drop pill rounding, industrial easy to operate, physical and chemical index is qualified.
Embodiment 6 cape jasmine, ginger and fermented soybean total extract preparation of soft capsule
Take by weighing in proportion in the putting glue jars such as gelatin, glycerol, water, 40-80 ℃ of water-bath glue, be molten state after, stir opacifiers such as adding titanium dioxide down, toners such as cacao brown.To be mixed evenly after, evacuation removes bubble.Glue and the cape jasmine, ginger and fermented soybean total extract handled well are added in capsule machine glue bucket and the hopper compacting respectively.Soft gelatin capsule was put to the high and dry chamber dry 24 hours, got qualified soft gelatin capsule promptly.
Embodiment 7. cape jasmine, ginger and fermented soybean total extract xylol cause the influence that the swelling of mice auricular concha and histamine cause ankle swelling in rat
Table 1, table 2 result of the test show, can be observed the pathological tissues swelling degree that embodiment 1 can obviously alleviate animal due to the modeling on animal mice, rat, and this result shows and is subjected to the reagent thing that certain antiinflammatory action is arranged.
Each medicine of table 1 is to the influence of mice auricular concha swelling
| Group | Dosage (mg/kg) | The example number | Cause scorching back two ear weight differences (mg) |
| Matched group | - | 10 | 19.5±2.3 |
| The aspirin group | 30 | 10 | 9.8±3.3** |
| Embodiment 1 | 200 | 10 | 13.0±1.9* |
| Embodiment 1 | 100 | 10 | 15.8±2.5* |
| Embodiment 1 | 50 | 10 | 17.65±4.2 |
Each medicine of table 2 is to the influence of ankle swelling in rat
| Group | Dosage (mg/kg) | The example number | Cause scorching back 1.0h two swollen ankles poor (cm) |
| Matched group | - | 10 | 9.7±1.3 |
| The aspirin group | 25 | 10 | 3.8±4.5** |
| Embodiment 1 | 180 | 10 | 5.9±1.5* |
| Embodiment 1 | 90 | 10 | 6.1±0.9* |
| Embodiment 1 | 45 | 10 | 7.8±2.8 |
Annotate: compare * * P＜0.01 with matched group, * P＜0.05.
The collaborative pentobarbital sodium threshold of embodiment 8. cape jasmine, ginger and fermented soybean total extracts reaches the influence of threshold dose to the mice hypnosis time down
Table 3 result of the test shows that the cape jasmine, ginger and fermented soybean total extract can obviously prolong the length of one's sleep of mice under the pentobarbital sodium threshold dose; During the pentobarbital sodium sub-threshold dose, the cape jasmine, ginger and fermented soybean total extract can obviously increase the sleeping number of elements of mice, and this result shows and is subjected to the reagent thing that certain sedative-hypnotic effect is arranged.
The collaborative pentobarbital sodium of each medicine of table 3 is to the influence of mice sleep
| Group | Dosage (mg/kg) | The threshold dose min length of one's sleep | The sub-threshold dose number of animals of falling asleep | The sub-threshold dose rate % that falls asleep |
| Matched group | - | 28±10 | 2 | 20 |
| Embodiment 1 | 200 | 49±9* | 7 | 70* |
| Embodiment 1 | 100 | 44±10* | 5 | 50* |
| Embodiment 1 | 50 | 39±5 | 3 | 30 |
Annotate: compare * * P＜0.01 with matched group, * P＜0.05.
Embodiment 9. cape jasmine, ginger and fermented soybean total extracts are to the influence (carbon powder method) of mouse small intestine progradation,
Table 4 result of the test shows that the cape jasmine, ginger and fermented soybean total extract can obviously promote the progradation of mice intestinal, shows to be subjected to the reagent thing that certain promotion gastro-intestinal digestion creeping effect is arranged.
Each medicine of table 4 is to the propulsive influence of mice intestinal
| Group | Number of elements only | Dosage mg/kg | Carbon powder advances length cm | Advance percentage rate % |
| Blank group motilium group embodiment 1 embodiment 1 embodiment 1 | 10 10 10 10 10 | 20 200 100 50 | 21.13±3.09 23.42±2.22 23.78±4.58 27.05±3.27 25.47±1.84 | 68.4±10.2 84.1±9.8* 79.3±7.6* 78.5±8.6* 74.4±10.4 |
Annotate: compare * * P＜0.01 with the blank group, * P＜0.05.
Embodiment 10. cape jasmine, ginger and fermented soybean total extracts are to the influence (writhing method) of mice analgesic activity
(1) experiment purpose
Table 5 result of the test shows that the cape jasmine, ginger and fermented soybean total extract can obviously reduce obvious minimizing mouse writhing number of times, and this result shows and be subjected to the reagent thing can resist the spasmic pain that glacial acetic acid causes that the animal brain nervous system is had certain analgesic activity.
Each medicine of table 5 is to the influence of mice analgesic activity
| Group | Dosage mg/kg | The animal number of elements only | Incubation period branch | Turn round the body number of times |
| Blank group | - | 15 | 5.47±1.55 | 30.12±10.04 |
| The tramadol group | 20 | 15 | 4.15±3.48 | 0.92±2.31** |
| Embodiment 1 | 200 | 15 | 5.89±2.15 | 20.37±8.89** |
| Embodiment 1 | 100 | 15 | 7.25±4.01 | 21.22±15.37* |
| Embodiment 1 | 50 | 15 | 5.01±3.25 | 18.69±12.23* |
Annotate: compare * * P＜0.01 with the blank group, * P＜0.05.
Embodiment 11. cape jasmine, ginger and fermented soybean total extracts are to rat gastric juice, pepsic influence test
Table 6 result of the test shows that the cape jasmine, ginger and fermented soybean total extract can significantly improve the effect of pepsin activity, shows to be subjected to the reagent thing that the digestive function that improves body is had certain facilitation.
Each medicine of table 6 is to rat gastric juice, pepsic influence
| Group | Number of elements | Dosage mg/kg | Gastric juice amount ml | The protease activity unit of force |
| Model group cimetidine embodiment 1 embodiment 1 embodiment 1 | 9 10 10 10 10 | 80 300 150 75 | 3±2 5±1 8±2 6±3 4±2 | 115±21 154±34 180±64* 179±28* 146±55 |
Annotate: compare * * P＜0.01 with model group, * P＜0.05.
Claims (10)
1. compound total extract of compound cape jasmine, ginger and fermented soybean, it mainly contains the 5%-95% iridoid glycosides, 1%-90% Saponin, 1%-90% terpenoid, 1%-90% flavonoid and 1%-90% volatile oil; Wherein said iridoid glycoside apoplexy due to endogenous wind contains the 10%-95% gardenoside, mainly contains soyasaponins in the Saponin, mainly contains (4-hydroxy-3-methoxyphenyl)ethyl methyl ketone in the terpenoid, mainly contains soybean isoflavone in the flavonoid, mainly contains gingerol and zingiberene in the volatile oil.
2. compound total extract of compound cape jasmine, ginger and fermented soybean according to claim 1, wherein gardenoside content is 10%-80%, and soybean isoflavone is 2%-10%, and gingerol is 1%-8%.
3. the preparation method of claim 1 or 2 described compound total extract of compound cape jasmine, ginger and fermented soybean is characterized in that concentrating after Fructus Gardeniae, Semen Sojae Preparatum and Rhizoma Zingiberis Recens are with solvent extraction centrifugal, and after the macroporous resin column solvent elution, concentrate drying gets final product.
4. the preparation method of claim 1 or 2 described compound total extract of compound cape jasmine, ginger and fermented soybean is characterized in that Fructus Gardeniae, Semen Sojae Preparatum and Rhizoma Zingiberis Recens place the supercritical CO 2 abstraction instrument, adds solvent extraction.
5. the preparation method of compound total extract of compound cape jasmine, ginger and fermented soybean according to claim 4, wherein said resin is a D-101 type adsorbent resin, XAD-2 type adsorbent resin, CHP-20P type adsorbent resin, SP825 type adsorbent resin or HP-20 type adsorbent resin.
6. according to the preparation method of claim 3 or 4 described compound total extract of compound cape jasmine, ginger and fermented soybean, the weight fraction ratio of wherein said Fructus Gardeniae, Semen Sojae Preparatum and Rhizoma Zingiberis Recens is 1 part-5 parts: 1 part-3 parts: 1 part-5 parts.
7. according to the preparation method of claim 3 or 4 described compound total extract of compound cape jasmine, ginger and fermented soybean, wherein said solvent is the one or more combination in water, methanol, ethanol, n-butyl alcohol, the acetone.
8. compound recipe cape jasmine, ginger and fermented soybean extract formulation is characterized in that containing claim 1 or 2 described compound recipe cape jasmine, ginger and fermented soybean extract and pharmaceutically acceptable carriers.
9. compound recipe cape jasmine, ginger and fermented soybean extract formulation according to claim 8, the dosage form of described preparation is a tablet, drop pill, capsule, exterior-applied emulsion, plaster, gel or injection.
10. claim 1 or 2 described compound recipe cape jasmine, ginger and fermented soybean extracts are treated spiritual neural class disease such as neurasthenia at the described extract of preparation treatment in preparation, anxiety neurosis, depression etc., respiratory system disease such as influenza, upper respiratory tract infection etc., digestive system disease such as acute or chronic gastritis, bacillary dysentery, gastric ulcer, dyspepsia, vomiting, gallbladder inflammation and polyp, jaundice etc., person in middle and old age's common disease such as hypomnesis, senile dementia, climacteric syndrome, osteoporosis, insomnia, hepatitis, coronary heart disease, hyperlipidemia, hypertension, heart failure, tumors etc. also have dermatological department and surgical diseases such as dermatitis, alopecia, acne, chloasma, mucocutaneous antibacterial, the application in the medicine of burning of fungal infection or wound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100112498A CN1840162B (en) | 2006-01-23 | 2006-01-23 | Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100112498A CN1840162B (en) | 2006-01-23 | 2006-01-23 | Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1840162A true CN1840162A (en) | 2006-10-04 |
| CN1840162B CN1840162B (en) | 2010-08-11 |
Family
ID=37029466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100112498A Expired - Fee Related CN1840162B (en) | 2006-01-23 | 2006-01-23 | Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1840162B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2772245A1 (en) | 2013-02-27 | 2014-09-03 | Symrise AG | Ginger extract for the protection of stem cells |
| CN104147183A (en) * | 2014-07-18 | 2014-11-19 | 中国人民解放军第二军医大学 | Method for separating and purifying total iridoid glycosides and total soy isoflavones from capejasmine and fermented soybean decoction |
| CN105030754A (en) * | 2015-07-07 | 2015-11-11 | 中国药科大学 | Pharmaceutical composition with anti-inflammatory activity and use thereof |
| EP3097905A1 (en) | 2015-05-28 | 2016-11-30 | Symrise AG | Cosmetic compositions |
| WO2017215729A1 (en) | 2016-05-30 | 2017-12-21 | Symrise Ag | Cosmetic compositions comprising sclareolide |
| CN109329530A (en) * | 2018-12-20 | 2019-02-15 | 株洲千金药业股份有限公司 | Rattan chrysanthemum granules and its preparation method and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100548331C (en) * | 2003-08-08 | 2009-10-14 | 北京德润六合医药科技有限公司 | Compound recipe Cape jasmine fermented soya beans, salted or other wise total extract and preparation and purposes |
-
2006
- 2006-01-23 CN CN2006100112498A patent/CN1840162B/en not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2772245A1 (en) | 2013-02-27 | 2014-09-03 | Symrise AG | Ginger extract for the protection of stem cells |
| CN104147183A (en) * | 2014-07-18 | 2014-11-19 | 中国人民解放军第二军医大学 | Method for separating and purifying total iridoid glycosides and total soy isoflavones from capejasmine and fermented soybean decoction |
| CN104147183B (en) * | 2014-07-18 | 2016-08-24 | 中国人民解放军第二军医大学 | A kind of isolated and purified total iridoid glycoside and method of total soybean isoflavone from the Decoction of Capejasmine and Fermented Soybean |
| EP3097905A1 (en) | 2015-05-28 | 2016-11-30 | Symrise AG | Cosmetic compositions |
| WO2016189046A1 (en) | 2015-05-28 | 2016-12-01 | Symrise Ag | Cosmetic compositions comprising purple coneflower pressed juice |
| WO2016189038A1 (en) | 2015-05-28 | 2016-12-01 | Symrise Ag | Cosmetic compositions comprising ginger root extracts |
| WO2016189024A1 (en) | 2015-05-28 | 2016-12-01 | Symrise Ag | Cosmetic compositions comprising sclareolide |
| CN105030754A (en) * | 2015-07-07 | 2015-11-11 | 中国药科大学 | Pharmaceutical composition with anti-inflammatory activity and use thereof |
| CN105030754B (en) * | 2015-07-07 | 2017-08-22 | 中国药科大学 | A kind of pharmaceutical composition and its application with anti-inflammatory activity |
| WO2017215729A1 (en) | 2016-05-30 | 2017-12-21 | Symrise Ag | Cosmetic compositions comprising sclareolide |
| CN109329530A (en) * | 2018-12-20 | 2019-02-15 | 株洲千金药业股份有限公司 | Rattan chrysanthemum granules and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1840162B (en) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1840166A (en) | Wendan decoction modern traditional Chinese medicine oral preparation and production method thereof | |
| CN103127232A (en) | Total extract for mulberry leaf prescription as well as preparation and usage thereof | |
| CN1840162B (en) | Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use | |
| CN111840363A (en) | Novel natto health-care composition assisting in reducing blood sugar and preparation method and application thereof | |
| CN1242807C (en) | Immunoregulator for resisting I-type allergic reaction and its preparing process | |
| CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN1839976A (en) | Compound saponin and flavone extract and its formulation and uses | |
| CN1621080A (en) | Medicine for abstaining from drug addiction and its preparation | |
| CN103830374B (en) | The application in hyperuricemia clearly of three leaf glycolipids | |
| CN100548332C (en) | Compound extractive of general glycoside of Cape jasmine and preparation thereof and purposes | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN101152223A (en) | Use of poplar leaf phenolic extract in treating cardiovascular diseases and its extraction method | |
| CN101564431B (en) | Chinese medicament preparation for keeping fit, resisting fatigue and fighting senium and producing method thereof | |
| CN1927289A (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and its preparation | |
| KR101093006B1 (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same | |
| CN101766676B (en) | A kind of jacaranda extract, its preparation method and its composition and application | |
| CN112274586A (en) | A traditional Chinese medicine compound preparation for treating liver fibrosis and its preparation method and application | |
| CN1548142A (en) | Drug for improving glucose tolerance and treating diabetes and obesity and preparation method thereof | |
| CN1742775A (en) | Medicine composition for preventing and treating orthopedic diseases | |
| CN104107352A (en) | Chinese herbal medicine for blood pressure reducing, and administration method thereof | |
| KR102439636B1 (en) | Composition for alleviating muscle tics and depression and manufacturing method thereof | |
| CN102198162B (en) | Traditional Chinese medicine composition for treating coronary heart disease, and preparation method thereof | |
| CN1857373A (en) | Tranquilizing Chinese medicine composition and its preparing method and application | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1440802A (en) | Gastritis treating Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhao Xiaoang Document name: patent for invention |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100811 Termination date: 20150123 |
|
| EXPY | Termination of patent right or utility model |